Abstract Objective Endothelial dysfunction is present in ankylosing spondylitis (AS).
Introduction

Ankylosing spondylitis (AS) is a chronic inflammatory disease of the spine and sacroiliac joints of unknown etiology (1). AS may affect extraarticular tissues such as eyes
, digestive tract, heart, and kidneys (2) . The severity of cardiac involvement varies greatly ranging from asymptomatic to severe considerable problems such as severe heart failure, and arrhythmias (3) . Some studies revealed an increased prevalence of cardiovascular (CV) mortality in AS (4) (5) (6) (7) (8) . Re- 
cently, an impaired endothelial function, by using ultrasonography, has been demonstrated in a relatively young age group of AS patients without known classical CV risk factors (9). However the etiology of events is still unclear. In this study, we aimed to determine the blood markers of asymmetric dimethylarginine (ADMA), a marker in nitric oxide (NO) metabolism, and endothelin-1 (ET-1) in AS patients, who were free of CV risk factors. We also investigated the effects of conventional and anti-tumor necrosis factor alpha (TNF-α) treatments on ADMA and ET-1 levels.
Materials and Methods
Patients and controls
The sample size was calculated by using the results of previous studies that investigated the levels of ADMA (10) (11) (12) , and ET-1 (13) (14) (15) Results were presented as mean±SD, and † median±IQR. p values <0.05 accepted as statistically significant. *Indicates a significant difference between AS patients with conventional treatment and healthy controls. **Denotes a significant difference between AS patients with anti-TNF treatment and healthy subjects. (20, 21) . Elevated ADMA accompanies several CV risk factors including hypertension, dyslipidemia, smoking, insulin resistance and diabetes (20, 21) . In addition to accompanying the traditional risk factors, it is also recognized as a novel CV risk parameter, as prospective studies have shown that increased ADMA is associated with a 3-to 5-fold increase in the risk of experiencing serious CV events even in clinically healthy non smoking subjects (20, 22 (20, 22) . In the literature, increased ADMA concentrations have been reported in various inflammatory rheumatic diseases including rheumatoid arthritis (RA) (10), Behcet's disease (12) , familial Mediterranean fever (FMF) (11) , systemic lupus erythematosus (SLE) (23) and scleroderma (24) . (27) . Elevated ET-1 levels have been reported in inflammatory rheumatic diseases particularly in scleroderma (28) , SLE (14) , Behcet's disease (15) and RA (13) 
Other measurements
Spinal mobility was assessed by the Bath Ankylosing Spondylitis Metrology Index (17). Patients were also evaluated with the Bath Ankylosing Spondylitis Functional Index (BASFI) (18) and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (19). BMI and waist circumfer-
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